Breaking Finance News

Trevena Inc (NASDAQ:TRVN) has been downgraded to Sell in a report by Zacks Investment Research today.

Yesterday Trevena Inc (NASDAQ:TRVN) traded -0.16% lower at $6.73. The company’s 50-day moving average is $6.91 and its 200-day moving average is $7.20. The last stock close price is down -10.66% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 172,276 shares of the stock were exchanged, down from an average trading volume of 288,565

Zacks Investment Research has downgraded Trevena Inc (NASDAQ:TRVN) to Sell in a report released on 10/6/2016.

See Chart Below

Trevena Inc (NASDAQ:TRVN)

Trevena Inc has a 52 week low of $5.58 and a 52 week high of $13.02 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 10 analysts have released a report on Trevena Inc. The 12-month price target is $14.55 with four analysts rating the company a strong buy, six analysts rating the company a buy, zero brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Trevena Inc (NASDAQ:TRVN)

Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *